Study of a new antibody for advanced tumors with FGFR1 protein
Part of Bones, joints & muscles, Cancer, Genetic & congenital, Kidney & urinary, Lungs & breathing, Skin, Women’s health & pregnancy clinical trials.
This trial tests an experimental antibody, OM-RCA-01, in people with advanced solid tumors that have high levels of a protein called FGFR1. It aims to see if the drug is safe and effective for those who have already tried other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older and weigh at least 50 kg.
- Your tumor must be one of these types: clear-cell kidney cancer, certain lung cancers (without EGFR/ALK mutations), prostate cancer, breast cancer (with known hormone receptor status), or head and neck cancers.
- Your tumor must show high FGFR1 protein levels (2+ or higher) on a special lab test.
- Your cancer must have worsened after at least two prior treatments, or you cannot have standard treatments.
- You must have at least one measurable tumor (seen on scans) and be in generally good health (ECOG score 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug that targets a protein called MET found on some cancer cells. It may help people with certain advanced cancers that have not responded to other treatments.
This study tests an experimental oral drug (CSCJC3456) that may target certain genetic changes (FGFR) in advanced cancers. It might be an option if your cancer has not improved with standard treatments.
This trial tests a new drug, MRG006A, for people with advanced solid tumors, especially liver cancer. It aims to see if the drug is safe and effective by targeting a protein called GPC3 found on some cancer cells.
This study tests an experimental drug (LNF1901) for people with advanced cancers that haven't responded to standard treatments. The goal is to see if it is safe and how well it works, and it might help control the cancer or shrink tumors.
This trial tests a new drug called MR001, which is designed to help your immune system fight cancer, in people with advanced solid tumors that have not responded to other treatments. It may be an option if standard treatments have stopped working or caused too many side effects.
This study tests a new drug, CRB-601-01, for people with advanced solid tumors that have not responded to other treatments. The goal is to see if it is safe and can help shrink tumors.
Hear when a new Non Small Cell Lung Cancer Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.